xT CDx: FDA-APPROVED TUMOR + NORMAL ASSAY NOW AVAILABLE TO ORDER /// LEARN MORE xT CDx: FDA-APPROVED TUMOR + NORMAL ASSAY NOW AVAILABLE TO ORDER /// LEARN MORE
09/20/2022

Patient recruitment at the speed of science

Learn how Sermonix Pharmaceuticals partnered with Tempus and its TIME network of clinical sites to accelerate patient recruitment for a phase 2 study.
Authors Sibel Blau, MD
President and CEO, Quality Cancer Care Alliance Network
Medical Director, Northwest Medical Specialties




Matthew Cooney, MD
Vice President, Therapeutic Development, Tempus

Read the full article here

Related Content

View more